drugset / Trial / NCT01887522
Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults
Phase 2
Terminated
144 enrolled
Gustave Roussy, Cancer Campus, Grand Paris
Innovative Therapies For Children with Cancer Consortium · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Multicenter, open label, prospective study including successively a phase I trial and then a phase II trial Phase I : Open label, non-randomized, sequential dose escalation of both drugs, vinblastine and nilotinib.
Timeline
- Start
- 2016-07-06
- Primary completion
- 2019-04-20
- Completion
- 2021-04-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nilotinib | Small molecule | 115 mg/m2 | Oral |
| Subject | Vinblastine | Small molecule | 3 mg/m2 | Intravenous |
| Subject | Vinblastine | Small molecule | 6 mg/m2 | Intravenous |